WHO Model Prescribing Information: Drugs Used in HIV-Related Infections
(1999; 58 pages) View the PDF document
Table of Contents
View the documentPreface
Open this folder and view contentsOpportunistic infections
Open this folder and view contentsRespiratory disease
Open this folder and view contentsNeurological disorders
Open this folder and view contentsOpthalmological complications
Open this folder and view contentsFebrile illness
Open this folder and view contentsGastrointestinal tract/diarrhoeal disease
Open this folder and view contentsMucocutaneous and cutaneous eruptions
Close this folderDrugs
View the documentAciclovir
View the documentAlbendazole
View the documentAmphotericin B
View the documentAzithromycin
View the documentBenzylpenicillins
View the documentCalcium folinate
View the documentCeftriaxone
View the documentCiprofloxacin
View the documentClarithromycin
View the documentClindamycin
View the documentCodeine
View the documentDapsone
View the documentFluconazole
View the documentFlucytosine
View the documentFoscarnet
View the documentGanciclovir
View the documentItraconazole
View the documentKetoconazole
View the documentNystatin
View the documentPentamidine
View the documentPrimaquine
View the documentPyrimethamine
View the documentRifabutin
View the documentSulfadiazine
View the documentSulfadoxine/Pyrimethamine (Fansidar)
View the documentSulfamethoxazole/Trimethoprim (Cotrimoxazole)
View the documentTrimethoprim
View the documentBack Cover

Calcium folinate

Group: antidote to folinic acid antagonists
Tablet, 5 mg, 15 mg [EDL]

General information

Calcium folinate is a metabolically active, reduced form of folic acid that is rapidly absorbed and extensively metabolized in the liver to other folic acid derivatives.

Clinical information


To decrease the haematopoetic toxicity of pyrimethamine and other inhibitors of folic acid metabolism in patients with HIV infection.

Dosage and administration

Adults and children: 5-50 mg/day dose adjusted according to patients blood counts.


The possibility of pernicous anaemia should always be excluded before starting treatment with calcium folinate. Its use obscures the diagnosis by rectifying the characteristic megaloblastic anaemia but it does not prevent neurological damage.

Use in pregnancy

Calcium folinate should always be used when pyrimethamine and sulfonamides are administered during pregnancy.

Adverse effects

Calcium folinate is generally well-tolerated. Rarely, hypersensitivity reactions occur, including urticaria, rash and pruritus.


Tablets should be stored in tightly closed containers protected from light.

to previous section
to next section
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: December 6, 2017